At-Home Drug of Abuse (DOA) Testing Market Size, Share & Trends Analysis Report By Application (,Urine,Saliva,Hair,Others), By Type (,Test Cups,Test Dip Cards,Test Strips,), By Region, And Segment Forecasts Till - 2030

Table Of Contents

1 Report Overview

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by At-Home Drug of Abuse (DOA) Testing Revenue
1.4 Market Analysis by Type
1.4.1 Global At-Home Drug of Abuse (DOA) Testing Market Size Growth Rate by Type: 2022 VS 2030
1.4.2 Test Cups
1.4.3 Test Dip Cards
1.4.4 Test Strips
1.4.5 Others
1.5 Market by Application
1.5.1 Global At-Home Drug of Abuse (DOA) Testing Market Share by Application: 2022-2030
1.5.2 Urine
1.5.3 Saliva
1.5.4 Hair
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global At-Home Drug of Abuse (DOA) Testing Market
1.8.1 Global At-Home Drug of Abuse (DOA) Testing Market Status and Outlook (2017-2030)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global At-Home Drug of Abuse (DOA) Testing Production Capacity Market Share by Manufacturers (2017-2022)
2.2 Global At-Home Drug of Abuse (DOA) Testing Revenue Market Share by Manufacturers (2017-2022)
2.3 Global At-Home Drug of Abuse (DOA) Testing Average Price by Manufacturers (2017-2022)
2.4 Manufacturers At-Home Drug of Abuse (DOA) Testing Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global At-Home Drug of Abuse (DOA) Testing Sales Volume Market Share by Region (2017-2022)
3.2 Global At-Home Drug of Abuse (DOA) Testing Sales Revenue Market Share by Region (2017-2022)
3.3 North America At-Home Drug of Abuse (DOA) Testing Sales Volume
3.3.1 North America At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.3.2 North America At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.4 East Asia At-Home Drug of Abuse (DOA) Testing Sales Volume
3.4.1 East Asia At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.4.2 East Asia At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.5 Europe At-Home Drug of Abuse (DOA) Testing Sales Volume (2017-2022)
3.5.1 Europe At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.5.2 Europe At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.6 South Asia At-Home Drug of Abuse (DOA) Testing Sales Volume (2017-2022)
3.6.1 South Asia At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.6.2 South Asia At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.7 Southeast Asia At-Home Drug of Abuse (DOA) Testing Sales Volume (2017-2022)
3.7.1 Southeast Asia At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.7.2 Southeast Asia At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.8 Middle East At-Home Drug of Abuse (DOA) Testing Sales Volume (2017-2022)
3.8.1 Middle East At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.8.2 Middle East At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.9 Africa At-Home Drug of Abuse (DOA) Testing Sales Volume (2017-2022)
3.9.1 Africa At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.9.2 Africa At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.10 Oceania At-Home Drug of Abuse (DOA) Testing Sales Volume (2017-2022)
3.10.1 Oceania At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.10.2 Oceania At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.11 South America At-Home Drug of Abuse (DOA) Testing Sales Volume (2017-2022)
3.11.1 South America At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.11.2 South America At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.12 Rest of the World At-Home Drug of Abuse (DOA) Testing Sales Volume (2017-2022)
3.12.1 Rest of the World At-Home Drug of Abuse (DOA) Testing Sales Volume Growth Rate (2017-2022)
3.12.2 Rest of the World At-Home Drug of Abuse (DOA) Testing Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
4 North America
4.1 North America At-Home Drug of Abuse (DOA) Testing Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia At-Home Drug of Abuse (DOA) Testing Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe At-Home Drug of Abuse (DOA) Testing Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia At-Home Drug of Abuse (DOA) Testing Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia At-Home Drug of Abuse (DOA) Testing Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East At-Home Drug of Abuse (DOA) Testing Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa At-Home Drug of Abuse (DOA) Testing Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania At-Home Drug of Abuse (DOA) Testing Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America At-Home Drug of Abuse (DOA) Testing Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World At-Home Drug of Abuse (DOA) Testing Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global At-Home Drug of Abuse (DOA) Testing Sales Volume Market Share by Type (2017-2022)
14.2 Global At-Home Drug of Abuse (DOA) Testing Sales Revenue Market Share by Type (2017-2022)
14.3 Global At-Home Drug of Abuse (DOA) Testing Sales Price by Type (2017-2022)
15 Consumption Analysis by Application
15.1 Global At-Home Drug of Abuse (DOA) Testing Consumption Volume by Application (2017-2022)
15.2 Global At-Home Drug of Abuse (DOA) Testing Consumption Value by Application (2017-2022)
16 Company Profiles and Key Figures in At-Home Drug of Abuse (DOA) Testing Business
16.1 UCP Biosciences
16.1.1 UCP Biosciences Company Profile
16.1.2 UCP Biosciences At-Home Drug of Abuse (DOA) Testing Product Specification
16.1.3 UCP Biosciences At-Home Drug of Abuse (DOA) Testing Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.2 Orient New Life Medical
16.2.1 Orient New Life Medical Company Profile
16.2.2 Orient New Life Medical At-Home Drug of Abuse (DOA) Testing Product Specification
16.2.3 Orient New Life Medical At-Home Drug of Abuse (DOA) Testing Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.3 Express Diagnostics Int’l
16.3.1 Express Diagnostics Int’l Company Profile
16.3.2 Express Diagnostics Int’l At-Home Drug of Abuse (DOA) Testing Product Specification
16.3.3 Express Diagnostics Int’l At-Home Drug of Abuse (DOA) Testing Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.4 Assure Tech (Hangzhou)
16.4.1 Assure Tech (Hangzhou) Company Profile
16.4.2 Assure Tech (Hangzhou) At-Home Drug of Abuse (DOA) Testing Product Specification
16.4.3 Assure Tech (Hangzhou) At-Home Drug of Abuse (DOA) Testing Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.5 Psychemedics Corporation
16.5.1 Psychemedics Corporation Company Profile
16.5.2 Psychemedics Corporation At-Home Drug of Abuse (DOA) Testing Product Specification
16.5.3 Psychemedics Corporation At-Home Drug of Abuse (DOA) Testing Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.6 Confirm BioSciences
16.6.1 Confirm BioSciences Company Profile
16.6.2 Confirm BioSciences At-Home Drug of Abuse (DOA) Testing Product Specification
16.6.3 Confirm BioSciences At-Home Drug of Abuse (DOA) Testing Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.7 Phamatech
16.7.1 Phamatech Company Profile
16.7.2 Phamatech At-Home Drug of Abuse (DOA) Testing Product Specification
16.7.3 Phamatech At-Home Drug of Abuse (DOA) Testing Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.8 Home Health (U.K.) Ltd.
16.8.1 Home Health (U.K.) Ltd. Company Profile
16.8.2 Home Health (U.K.) Ltd. At-Home Drug of Abuse (DOA) Testing Product Specification
16.8.3 Home Health (U.K.) Ltd. At-Home Drug of Abuse (DOA) Testing Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.9 Quest Products
16.9.1 Quest Products Company Profile
16.9.2 Quest Products At-Home Drug of Abuse (DOA) Testing Product Specification
16.9.3 Quest Products At-Home Drug of Abuse (DOA) Testing Production Capacity, Revenue, Price and Gross Margin (2017-2022)
17 At-Home Drug of Abuse (DOA) Testing Manufacturing Cost Analysis
17.1 At-Home Drug of Abuse (DOA) Testing Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of At-Home Drug of Abuse (DOA) Testing
17.4 At-Home Drug of Abuse (DOA) Testing Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 At-Home Drug of Abuse (DOA) Testing Distributors List
18.3 At-Home Drug of Abuse (DOA) Testing Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of At-Home Drug of Abuse (DOA) Testing (2022-2030)
20.2 Global Forecasted Revenue of At-Home Drug of Abuse (DOA) Testing (2022-2030)
20.3 Global Forecasted Price of At-Home Drug of Abuse (DOA) Testing (2017-2030)
20.4 Global Forecasted Production of At-Home Drug of Abuse (DOA) Testing by Region (2022-2030)
20.4.1 North America At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.4.2 East Asia At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.4.3 Europe At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.4.4 South Asia At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.4.5 Southeast Asia At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.4.6 Middle East At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.4.7 Africa At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.4.8 Oceania At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.4.9 South America At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.4.10 Rest of the World At-Home Drug of Abuse (DOA) Testing Production, Revenue Forecast (2022-2030)
20.5 Forecast by Type and by Application (2022-2030)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2030)
20.5.2 Global Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Application (2022-2030)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Country
21.2 East Asia Market Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Country
21.3 Europe Market Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Countriy
21.4 South Asia Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Country
21.5 Southeast Asia Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Country
21.6 Middle East Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Country
21.7 Africa Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Country
21.8 Oceania Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Country
21.9 South America Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Country
21.10 Rest of the world Forecasted Consumption of At-Home Drug of Abuse (DOA) Testing by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer